Navigation Links
Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
Date:6/2/2008

GSK exercises option for AM803, a FLAP inhibitor which recently completed

phase I studies

SAN DIEGO, June 2 /PRNewswire/ -- Amira Pharmaceuticals today announced that under the terms of a worldwide exclusive agreement entered into in Feb 2008, GlaxoSmithKline (GSK) will exercise its right to a second FLAP compound, AM803. Under the original agreement, GSK has rights to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein) inhibitors for the treatment of respiratory and cardiovascular disease. The decision to develop AM803 follows the successful completion of a phase I study by Amira, which demonstrated its potential as a once-daily FLAP inhibitor.

"Exercise of this option by GSK caps a productive first few months during which Amira has hit a number of near term milestones. Hitting these milestones early has not only further strengthened our relations with GSK, but has resulted in meaningful economic benefit to Amira," said Hari Kumar, Chief Business Officer, Amira. "The project has started extremely well and we are very pleased at the commitment of GSK and the progression of development."

About FLAP Inhibitors

FLAP (5-Lipoxygenase Activating Protein) is a key component early in the leukotriene pathway, a complex signaling process that exerts control over biological processes, such as inflammation and immunity. Excessive production of leukotrienes exacerbates inflammatory diseases, such as asthma; the FLAP gene has also been linked to a significant increase in the risk of myocardial infarction and stroke. AM103 and AM803 bind to FLAP, inhibiting the synthesis of leukotrienes that cause inflammation.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the eicosanoid pathway.

The company co
'/>"/>

SOURCE Amira Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
2. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
3. Amira Pharmaceuticals Appoints First Vice President of Development
4. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
5. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
6. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
7. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
8. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
9. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
10. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
11. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... (PRWEB) April 20, 2015 Saint Joseph Regional ... 15 Top Health Systems by Truven Health Analytics, a leading ... quality of healthcare. SJRMC has been recognized by Truven Health ... the past four years. , According to Truven Health Analytics' ... Health Systems, in matchups with their peers, set the standard ...
(Date:4/20/2015)... A recent cross-sectional survey ... list the top 10 most beneficial therapies for fibromyalgia, no ... most harmful therapies, only approved drugs were named. , ... help, their effect is only felt as long as the ... recent interview. , “On the other hand, aerobic exercise and ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Western ... Donahue, DNP, RN, NEA-BC, FAAN who was named ... Education and Research in September 2014, is transitioning ... Officer to lead the development of Western Connecticut ... newly created role, Donahue will be responsible for ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Advance Home ... a personal matter that many customers would prefer not to ... of March 30th a discreet delivery method allowing customers to ... arrive at their home without fear of a neighbor or ... shipping method is available now on all orders and no ...
(Date:4/20/2015)... Genuine fat loss results can seem virtually ... in the past. But what failed dieters and gym-goers don’t ... guaranteed by adhering to five simple principles. , 1. Nutrition, ... many hours one spends working at the gym, a poor ... a nutritional mean plan does not mean starvation, calorie counting ...
Breaking Medicine News(10 mins):Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 2Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 3Health News:Medical Doctor in Huntsville Reveals That Aerobic Exercise Offers Best Results in Fibromyalgia Treatment 2Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Guarantee Fat Loss Results With 5 Easy Tips 2Health News:Guarantee Fat Loss Results With 5 Easy Tips 3
... could lead to new targeted, individualized treatments, experts say ... have identified 26 genes associated with the most common ... the number of genes known to play a role ... in developing individualized ways of diagnosing and treating lung ...
... and OTTAWA, Oct. 22 iNutrition, a,healthy snack, ... provider, announced today that Ballyhoo, the internet marketing,and ... A,conference call will be announced soon with the ... Over 35,000 people have,already signed up for information ...
... which came into being in the seventies, evolved into an essential ... to increase with mounting pressure on pharma and biotech companies to ... is projected to exceed $26.2 billion by the year 2012. ... ...
... mother and gluten-free cook/author Theresa Santandrea-Cull - is a collection of ... and wheat products. , ... (PRWEB) October 22, 2008 ... latest recipe book "No Wheat? No Way!" she included ...
... experienced childhood physical or sexual abuse are more likely ... partner when they are adolescents and young adults. , ... risk for committing sexual coercion have found that being ... them 4 times more likely to engage in ...
... Nancy W. Dickey, MD,president of the Texas A&M Health ... Texas A&M University System, has been named chair of,the ... Centers., A former dean and current professor of ... Dickey is past president of the American,Medical Association and ...
Cached Medicine News:Health News:Researchers Find More Genes Linked to Lung Cancer 2Health News:Researchers Find More Genes Linked to Lung Cancer 3Health News:Ballyhoo to Lead and Launch Affiliate Marketing Program for iNutrition.com 2Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3Health News:Contract Research Outsourcing Market to Exceed $26.2 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 4Health News:Now Available Online, Beneficial Recipe Book Offers Wheat-Free, Gluten-Free Options for Healthy Living 2Health News:Child abuse increases risk for later sexually coercive behavior in some men 2Health News:Child abuse increases risk for later sexually coercive behavior in some men 3Health News:Association of Academic Health Centers Names Texas A&M's Dr. Nancy W. Dickey Chair of the Board of Directors 2
(Date:4/20/2015)... To Cancer (SU2C) and the American Cancer Society (ACS) announced ... the number one cancer killer in America, lung cancer, here ... Cancer Research (AACR), Scientific Partner to SU2C. ... States will be diagnosed with lung and bronchus ... lung cancer the leading cause of cancer deaths in both ...
(Date:4/20/2015)... April 20, 2015 Kalorama Information says ... continue to be robust; the market is driven ... expanding global markets, new product innovations and increasing ... steady market inhibitors, such as government restraints, limited ... environment. The healthcare market research publisher,s report, ...
(Date:4/20/2015)... Eli Lilly and Company (NYSE: LLY ) announced ... to placebo in the treatment of patients with active ... patients achieving an ACR 20 response. ACR 20 is ... in disease signs and symptoms as defined by the ... Phase 3 study, titled SPIRIT-P1, patients who were naïve ...
Breaking Medicine Technology:New SU2C-American Cancer Society Lung Cancer Dream Team Announced 2New SU2C-American Cancer Society Lung Cancer Dream Team Announced 3New SU2C-American Cancer Society Lung Cancer Dream Team Announced 4New SU2C-American Cancer Society Lung Cancer Dream Team Announced 5New SU2C-American Cancer Society Lung Cancer Dream Team Announced 6Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... FORT WASHINGTON, Pa., Dec. 28, 2010 ReSearch Pharmaceutical ... an agreement to sell the company to affiliates of ... an all cash transaction valued at $6.10 per share. ... acquisition agreement and recommended that RPS shareholders approve the ...
... Pa., Dec. 28, 2010 Crothall Healthcare, a ... announced its Preferred Partnership arrangement with 3M to ... Crothall Environmental Services teams will use a hand-held ... triphosphate) bioluminescense—the resulting reaction of organic material on ...
Cached Medicine Technology:ReSearch Pharmaceutical Services to be Acquired by Warburg Pincus 2ReSearch Pharmaceutical Services to be Acquired by Warburg Pincus 3ReSearch Pharmaceutical Services to be Acquired by Warburg Pincus 4Crothall Healthcare Selects 3M™ Clean-Trace™ for Infection Control Verification 2
Designed for use in traditional external approach DCRs in pediatric patients & for endoscopic DCRs in adults or children. Lumen 6.0mm long, ID-1.4mm (.12 in); OD-5.0mm (.20 in), Outer flanges 8.0mm ...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
...
...
Medicine Products: